China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SHE: 000999)

China Resources Sanjiu Medical & Pharmaceutical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019
Operating Revenue	24,970	23,837	17,411	14,825	13,093	14,320
Other Revenue	901.47	901.47	667.99	719.33	544.28	473.49
Revenue	25,871	24,739	18,079	15,544	13,637	14,794
Revenue Growth (YoY)	5.27%	36.83%	16.31%	13.98%	-7.82%	10.17%
Cost of Revenue	12,096	11,726	8,354	6,561	5,143	4,905
Gross Profit	13,775	13,013	9,725	8,984	8,494	9,889
Selling, General & Admin	8,507	8,489	6,135	5,992	5,947	7,540
Research & Development	768.24	714.5	593.94	560.2	459.84	441.88
Other Operating Expenses	243.98	262.72	207.05	204.39	175.49	206.11
Operating Expenses	9,632	9,521	6,942	6,770	6,602	8,201
Operating Income	4,143	3,492	2,784	2,214	1,892	1,688
Interest Expense	-93.95	-80.78	-21.23	-14.18	-5.09	-4.41
Interest & Investment Income	132.71	125.1	118.11	101.08	156.22	871.91
Currency Exchange Gain (Loss)	2.5	2.5	-56.25	-12.89	-9.68	-23.42
Other Non Operating Income (Expenses)	77.32	-17.44	-4.11	-1.11	-21.91	-19.68
EBT Excluding Unusual Items	4,262	3,521	2,820	2,287	2,012	2,513
Impairment of Goodwill	-	-	-65.51	-44.24	-174.95	-191.66
Gain (Loss) on Sale of Investments	-22.21	-28.63	2.58	5.04	6.87	0.61
Gain (Loss) on Sale of Assets	21.42	0.81	2.28	0.85	-2.69	-1.82
Asset Writedown	-64.31	-31.48	-34.3	-8.1	-7.95	-0.32
Other Unusual Items	292.43	292.43	237.69	202.96	225.89	233.66
Pretax Income	4,489	3,754	2,963	2,444	2,059	2,555
Income Tax Expense	766.32	580.97	466.43	345.41	441.89	429.55
Earnings From Continuing Operations	3,723	3,173	2,497	2,099	1,618	2,125
Minority Interest in Earnings	-312.85	-320.55	-48.21	-43.49	-20.04	-26.59
Net Income	3,410	2,853	2,449	2,055	1,597	2,099
Net Income to Common	3,410	2,853	2,449	2,055	1,597	2,099
Net Income Growth	17.63%	16.50%	19.16%	28.65%	-23.89%	46.56%
Shares Outstanding (Basic)	1,277	1,279	1,284	1,272	1,274	1,275
Shares Outstanding (Diluted)	1,277	1,279	1,284	1,272	1,274	1,275
Shares Change (YoY)	-0.65%	-0.37%	0.90%	-0.15%	-0.07%	-0.01%
EPS (Basic)	2.67	2.23	1.91	1.62	1.25	1.65
EPS (Diluted)	2.67	2.23	1.91	1.62	1.25	1.65
EPS Growth	18.40%	16.94%	18.09%	28.84%	-23.84%	46.58%
Free Cash Flow	3,575	3,335	2,055	1,012	1,602	1,411
Free Cash Flow Per Share	2.80	2.61	1.60	0.80	1.26	1.11
Dividend Per Share	2.154	1.154	0.769	0.656	0.385	0.331
Dividend Growth	180.01%	50.00%	17.26%	70.57%	16.26%	10.27%
Gross Margin	53.24%	52.60%	53.79%	57.79%	62.28%	66.85%
Operating Margin	16.02%	14.12%	15.40%	14.24%	13.87%	11.41%
Profit Margin	13.18%	11.53%	13.54%	13.22%	11.71%	14.19%
Free Cash Flow Margin	13.82%	13.48%	11.37%	6.51%	11.75%	9.54%
EBITDA	4,993	4,178	3,251	2,643	2,282	2,023
EBITDA Margin	19.30%	16.89%	17.98%	17.00%	16.73%	13.68%
D&A For EBITDA	849.61	685.71	467.17	429.17	390.19	335.18
EBIT	4,143	3,492	2,784	2,214	1,892	1,688
EBIT Margin	16.02%	14.12%	15.40%	14.24%	13.87%	11.41%
Effective Tax Rate	17.07%	15.47%	15.74%	14.13%	21.46%	16.81%
Revenue as Reported	25,871	24,739	18,079	15,544	13,637	14,794
Advertising Expenses	-	660.33	543.92	578.72	446.69	497.09

Source: S&P Capital IQ. Standard template. Financial Sources.